- Home
- ZEPP vs VYNE Comparison
ZEPP vs VYNE Comparison
Compare ZEPP & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- VYNE
- Stock Information
- Founded
- ZEPP 2013
- VYNE 2003
- Country
- ZEPP China
- VYNE United States
- Employees
- ZEPP N/A
- VYNE N/A
- Industry
- ZEPP Computer Manufacturing
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- ZEPP Technology
- VYNE Health Care
- Exchange
- ZEPP Nasdaq
- VYNE Nasdaq
- Market Cap
- ZEPP 48.8M
- VYNE 41.9M
- IPO Year
- ZEPP N/A
- VYNE 2018
- Fundamental
- Price
- ZEPP $2.91
- VYNE $3.46
- Analyst Decision
- ZEPP
- VYNE Strong Buy
- Analyst Count
- ZEPP 0
- VYNE 2
- Target Price
- ZEPP N/A
- VYNE $6.88
- AVG Volume (30 Days)
- ZEPP 12.0K
- VYNE 110.7K
- Earning Date
- ZEPP 11-18-2024
- VYNE 02-27-2025
- Dividend Yield
- ZEPP N/A
- VYNE N/A
- EPS Growth
- ZEPP N/A
- VYNE N/A
- EPS
- ZEPP N/A
- VYNE N/A
- Revenue
- ZEPP $208,946,095.00
- VYNE $493,000.00
- Revenue This Year
- ZEPP N/A
- VYNE $28.30
- Revenue Next Year
- ZEPP $18.94
- VYNE N/A
- P/E Ratio
- ZEPP N/A
- VYNE N/A
- Revenue Growth
- ZEPP N/A
- VYNE 39.27
- 52 Week Low
- ZEPP $2.06
- VYNE $1.57
- 52 Week High
- ZEPP $8.40
- VYNE $3.61
- Technical
- Relative Strength Index (RSI)
- ZEPP 50.54
- VYNE 69.72
- Support Level
- ZEPP $2.53
- VYNE $3.09
- Resistance Level
- ZEPP $3.10
- VYNE $3.40
- Average True Range (ATR)
- ZEPP 0.22
- VYNE 0.28
- MACD
- ZEPP 0.01
- VYNE 0.09
- Stochastic Oscillator
- ZEPP 65.79
- VYNE 88.16
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in two segments: Xiaomi Wearable Products and Self-branded products & others. The product portfolio includes smartwatches and fitness bands. The majority is from Self-branded products & other segments. It generates majority of the revenue from Xiaomi Wearable Products segment.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.